Longevity & Anti-Aging

Extensively Studied

NAD+

Coenzyme central to cellular-energy research.

Also known as: Nicotinamide Adenine Dinucleotide

Research dose range100–500 mg (research models)

Route studiedIV / subcutaneous

Study durationIntermittent or loading studies

Storage2–8 °C reconstituted

Overview

NAD+ is a coenzyme essential to cellular-energy metabolism and redox reactions, widely investigated in longevity, DNA-repair, and metabolic research.

Key research findings

A central redox coenzyme whose cellular levels decline with age. Research links NAD+ availability to sirtuin and PARP activity, mitochondrial function, and DNA repair; supplementation models (NAD+ or precursors like NMN/NR) report improved energy-metabolism markers.

Mechanism of action

Serves as an electron carrier in redox reactions and a substrate for sirtuins and PARPs, linking cellular energy to repair and signaling.

Molecular information

Weight663.43 Da

LengthDinucleotide (non-peptide)

TypePyridine dinucleotide coenzyme

NAD+ is a coenzyme, not a peptide; precursors (NMN, NR) are often studied for delivery.

Pharmacokinetics

Peak: ~minutes (IV)Half-life: Short (rapidly metabolized)Cleared: Hours

Peak · 0hHalf-life · 2h

Illustrative relative-concentration model derived from published pharmacokinetic research. Curve is normalized and provided for educational comparison only — not a dosing schedule.

Research applications

Cellular-energy and redox research
Sirtuin and DNA-repair studies
Longevity and metabolic investigations

Research protocols

Protocols summarized from published research models. Provided for scientific reference only — not dosing guidance for human use.

Research goalReference amountFrequencyRoute

Slow IV infusion referenceAmount: 100–500 mgFrequency: Per sessionRoute: IV (slow)

Subcutaneous referenceAmount: 50–100 mgFrequency: Daily–weeklyRoute: Subcutaneous

Observed effects timeline

Aggregated observations reported across research literature. Timing and magnitude vary by model and are not a guarantee of outcome.

Acute
Transient flushing/discomfort with rapid IV reported; slow infusion mitigates this in study settings.
Week 1–4
Reported improvements in energy and metabolic markers in supplementation models.
Ongoing
Sustained-precursor studies report maintained NAD+ pools over time.

Research compatibility

Describes how compounds are studied alongside one another in the literature. Not a recommendation to co-administer.

MOTS-c

Complementary mitochondrial-energy pathways.

Compatible

SS-31

Co-studied in mitochondrial-function research.

Compatible

Epitalon

Studied together in longevity contexts.

Compatible

BPC-157

Combined protocols enhance cellular repair and energy production

Synergistic

TB-500

Complementary effects on tissue regeneration and mitochondrial function

Synergistic

GLP-1

NAD+ supports metabolic pathways enhanced by GLP-1 agonists

Compatible

Ipamorelin

Growth hormone pathways benefit from improved cellular energy metabolism

Synergistic

CJC-1295 (No DAC)

Enhanced recovery and anti-aging effects when combined

Compatible

How to reconstitute

Important

Reconstitute gently and refrigerate. NAD+ is sensitive to heat; IV use is administered slowly to reduce discomfort in research settings.

1Allow the vial to reach room temperature.
2Swab the stopper with alcohol and let it air dry.
3Add the diluent slowly down the vial wall.
4Swirl gently until dissolved — do not shake.
5Refrigerate at 2–8 °C and protect from light.

Open reconstitution calculator

Quality indicators

Uniform powder

Lyophilized material should be white to off-white without discoloration.

Clear solution

Reconstitutes to a clear, colorless solution.

Slight clumping

Small clumps that dissolve completely with gentle swirling are acceptable — shipping can cause minor compaction.

Collapsed or melted appearance

Powder that looks collapsed, melted, or stuck to the vial walls may have been exposed to heat in transit.

Cloudy after reconstitution

Persistent cloudiness, particles, or precipitate after gentle mixing can indicate a degraded or contaminated peptide.

Reported observations & safety

Safety signals reported in the research literature. Compiled for scientific awareness — not medical advice.

Rapid IV administration commonly reports flushing, nausea, and chest pressure — slow infusion reduces these.
Generally well tolerated at research amounts in study settings.

References & further reading

NAD+ metabolism in health and disease (review)

Reviewsirtuins/PARPsaging

Overview of how NAD+ availability links cellular energy, repair enzymes, and age-related decline.

View study

Topics

coenzymelongevitycellular energy

This entry is provided for educational and informational purposes only. It is not medical advice, a dosing protocol, or a claim of therapeutic benefit. Research compounds are supplied strictly for laboratory and research use — not for human or veterinary consumption.

Research level

Extensively Studied

Large body of preclinical and clinical literature.

Quick reference

Dose range100–500 mg (research models)

RouteIV / subcutaneous

DurationIntermittent or loading studies

Storage2–8 °C reconstituted

Half-lifeShort (rapidly metabolized)

Available at Reviva

NAD+ is stocked as a research-grade compound, ≥99% by HPLC, third-party verified.

View in catalogue